Copyright: ©Author(s) 2026.
World J Hepatol. Oct 27, 2026; 18(10): 124577
Published online Oct 27, 2026. doi: 10.4254/wjh.124577
Published online Oct 27, 2026. doi: 10.4254/wjh.124577
Table 2 Clinical characteristics of elevated and non-elevated groups, n (%)
| Factor | Total cases (n = 430) | Non-elevated groups | Elevated groups (n = 158) | P value |
| HBeAg | 0.021 | |||
| Negative | 402 (93.49) | 260 (95.59) | 142 (89.87) | |
| Positive | 28 (6.51) | 12 (4.41) | 16 (10.13) | |
| HBV DNA (IU/mL) | < 0.001 | |||
| < 100 | 228 (53.02) | 181 (66.54) | 47 (29.75) | |
| ≥ 100 | 202 (46.98) | 91 (33.46) | 111 (70.25) | |
| TBA, µmol/L | 2.60 (1.46, 4.25) | 2.60 (1.40, 4.00) | 2.65 (1.80, 4.45) | 0.454 |
| TBIL, µmol/L | 5.75 (4.38, 7.62) | 5.80 (4.25, 7.80) | 5.65 (4.38, 7.50) | 0.530 |
| DBIL, µmol/L | 2.50 (1.91, 3.12) | 2.50 (2.00, 3.20) | 2.50 (1.90, 3.10) | 0.697 |
| IBIL, µmol/L | 3.10 (2.20, 4.70) | 3.10 (2.20, 4.95) | 3.10 (2.15, 4.55) | 0.636 |
| AST, U/L | 15.50 (13.50, 19.60) | 15.40 (13.20, 19.60) | 16.20 (13.60, 19.60) | 0.643 |
| AST < 19 | 251 (58.37) | 159 (58.46) | 92 (58.23) | 0.352 |
| AST ≥ 19 | 100 (23.26) | 58 (21.32) | 42 (26.58) | |
| ALT, U/L | 13.60 (9.80, 18.88) | 13.60 (9.75, 18.75) | 13.50 (9.75, 18.91) | 0.915 |
| ALT < 19 | 232 (53.95) | 140 (51.47) | 92 (58.23) | 0.958 |
| ALT ≥ 19 | 75 (17.44) | 45 (16.54) | 30 (18.99) | |
| TP, g/L | 65.71 ± 4.29 | 65.43 ± 3.85 | 66.04 ± 4.81 | 0.555 |
| ALB, g/L | 36.10 ± 3.81 | 36.11 ± 3.76 | 35.80 ± 3.92 | 0.980 |
| GLB, g/L | 30.30 ± 3.20 | 29.95 ± 318 | 30.68 ± 3.22 | 0.343 |
| HGB, g/L | 120.00 (113.00, 127.00) | 120.00 (113.00, 127.75) | 120.00 (113.50, 126.00) | 0.662 |
| PLT, × 109/L | 230.00 (201.00, 263.25) | 232.00 (201.00, 264.00) | 226.00 (201.50, 263.00) | 0.644 |
| WBC, × 109/L | 8.61 (7.54, 10.20) | 8.60 (7.58, 10.39) | 8.61 (7.36, 9.82) | 0.455 |
| TC, mmol/L | 4.73 (4.12, 5.26) | 4.69 (4.13, 5.23) | 4.83 (4.06, 5.33) | 0.622 |
| TG, mmol/L | 1.39 (1.12, 1.82) | 1.44 (1.17, 1.87) | 1.28 (1.03, 1.68) | 0.025 |
| HDL-C, mmol/L | 1.71 ± 0.29 | 1.70 ± 0.28 | 1.72 ± 0.61 | 0.678 |
| LDL-C, mmol/L | 2.36 (2.02, 2.76) | 2.36 (2.10, 2.70) | 2.38 (1.90, 2.81) | 0.920 |
| HbA1c, % | 5.10 (5.00, 5.30) | 5.10 (5.00, 5.30) | 5.10 (4.90, 5.30) | 0.429 |
| < 6.0 | 276 (64.19) | 177 (65.07) | 99 (62.66) | 0.060 |
| ≥ 6.0 | 2 (0.47) | 0 (0) | 2 (1.27) | |
| Cr, µmol/L | 49.00 (44.00, 54.00) | 48.70 (43.00, 54.00) | 50.00 (44.00, 55.00) | 0.333 |
| PT, seconds | 12.50 (11.10, 12.90) | 12.40 (11.20, 12.88) | 12.50 (11.05, 13.000 | 0.339 |
| APTT, seconds | 32.40 (28.80, 34.70) | 32.45 (28.85, 34.78) | 32.20 (28.80, 34.70) | 0.883 |
| INR | 0.95 (0.92, 0.99) | 0.95 (0.92, 0.99) | 0.96 (0.92, 0.99) | 0.380 |
- Citation: Chen Z, Chen H, Jie B, Peng T, Lin Y, Geng Y, Shen Y, Deng Y, Xie D, Yang L, Ouyang S. Risk factors and predictive model for hepatitis B virus deoxyribonucleic acid elevation in mid-to-late pregnancy with low viremia. World J Hepatol 2026; 18(10): 124577
- URL: https://www.wjgnet.com/1948-5182/full/v18/i10/124577.htm
- DOI: https://dx.doi.org/10.4254/wjh.124577